JP2020138964A - 近視進行抑制剤、機能性食品及び眼科用組成物 - Google Patents
近視進行抑制剤、機能性食品及び眼科用組成物 Download PDFInfo
- Publication number
- JP2020138964A JP2020138964A JP2020029934A JP2020029934A JP2020138964A JP 2020138964 A JP2020138964 A JP 2020138964A JP 2020029934 A JP2020029934 A JP 2020029934A JP 2020029934 A JP2020029934 A JP 2020029934A JP 2020138964 A JP2020138964 A JP 2020138964A
- Authority
- JP
- Japan
- Prior art keywords
- myopia
- omega
- progression
- acid
- axial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004515 progressive myopia Effects 0.000 title claims abstract description 33
- 239000003112 inhibitor Substances 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 235000013376 functional food Nutrition 0.000 title claims abstract description 13
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 44
- 229940012843 omega-3 fatty acid Drugs 0.000 claims abstract description 44
- 230000004329 axial myopia Effects 0.000 claims abstract description 34
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims abstract description 27
- 230000004323 axial length Effects 0.000 claims abstract description 23
- 239000000944 linseed oil Substances 0.000 claims abstract description 15
- 235000021388 linseed oil Nutrition 0.000 claims abstract description 15
- 239000003921 oil Substances 0.000 claims abstract description 14
- 235000019198 oils Nutrition 0.000 claims abstract description 14
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 12
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 12
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 11
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 11
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 11
- 235000004347 Perilla Nutrition 0.000 claims abstract description 8
- 244000124853 Perilla frutescens Species 0.000 claims abstract description 8
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 7
- 239000002552 dosage form Substances 0.000 claims abstract description 7
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 7
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 6
- 229940090949 docosahexaenoic acid Drugs 0.000 claims abstract description 5
- 230000037406 food intake Effects 0.000 claims abstract description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 4
- 239000006014 omega-3 oil Substances 0.000 claims description 17
- 208000030533 eye disease Diseases 0.000 claims description 4
- 208000001491 myopia Diseases 0.000 abstract description 24
- 230000004379 myopia Effects 0.000 abstract description 23
- 210000001110 axial length eye Anatomy 0.000 abstract 1
- 235000005911 diet Nutrition 0.000 description 32
- 230000037213 diet Effects 0.000 description 32
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 15
- 229940033080 omega-6 fatty acid Drugs 0.000 description 15
- 210000001508 eye Anatomy 0.000 description 14
- 235000013305 food Nutrition 0.000 description 12
- 210000000695 crystalline len Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000003549 soybean oil Substances 0.000 description 9
- 235000012424 soybean oil Nutrition 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 239000003889 eye drop Substances 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 239000003826 tablet Substances 0.000 description 6
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000002350 accommodative effect Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 210000005252 bulbus oculi Anatomy 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- KXVFBCSUGDNXQF-DZDBOGACSA-N (2z,4z,6z,8z,10z)-tetracosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C=C/C(O)=O KXVFBCSUGDNXQF-DZDBOGACSA-N 0.000 description 3
- 206010020675 Hypermetropia Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- AHANXAKGNAKFSK-PDBXOOCHSA-N all-cis-icosa-11,14,17-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O AHANXAKGNAKFSK-PDBXOOCHSA-N 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000004305 hyperopia Effects 0.000 description 3
- 201000006318 hyperopia Diseases 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 239000004158 L-cystine Substances 0.000 description 2
- 235000019393 L-cystine Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- HQPCSDADVLFHHO-LTKCOYKYSA-N all-cis-8,11,14,17-icosatetraenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HQPCSDADVLFHHO-LTKCOYKYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 208000003464 asthenopia Diseases 0.000 description 2
- HSWPZIDYAHLZDD-UHFFFAOYSA-N atipamezole Chemical compound C1C2=CC=CC=C2CC1(CC)C1=CN=CN1 HSWPZIDYAHLZDD-UHFFFAOYSA-N 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960004874 choline bitartrate Drugs 0.000 description 2
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000004340 degenerative myopia Effects 0.000 description 2
- 208000001309 degenerative myopia Diseases 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- VPNGEIHDPSLNMU-UHFFFAOYSA-N medetomidine hydrochloride Chemical compound Cl.C=1C=CC(C)=C(C)C=1C(C)C1=CNC=N1 VPNGEIHDPSLNMU-UHFFFAOYSA-N 0.000 description 2
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 2
- 229960003793 midazolam Drugs 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000004331 refractive myopia Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 2
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- NPTIBOCVSPURCS-RCHUDCCISA-N (9E,12E,15E,18E,21E)-tetracosa-9,12,15,18,21-pentaenoic acid Chemical compound CC\C=C\C\C=C\C\C=C\C\C=C\C\C=C\CCCCCCCC(O)=O NPTIBOCVSPURCS-RCHUDCCISA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- XYGVIBXOJOOCFR-BTJKTKAUSA-N (z)-but-2-enedioic acid;8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo[1,5-a][1,4]benzodiazepine Chemical compound OC(=O)\C=C/C(O)=O.C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F XYGVIBXOJOOCFR-BTJKTKAUSA-N 0.000 description 1
- LSIXBBPOJBJQHN-UHFFFAOYSA-N 2,3-Dimethylbicyclo[2.2.1]hept-2-ene Chemical compound C1CC2C(C)=C(C)C1C2 LSIXBBPOJBJQHN-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 208000028048 Accommodation disease Diseases 0.000 description 1
- AHANXAKGNAKFSK-UHFFFAOYSA-N Bishomo-a-linolenic acid Natural products CCC=CCC=CCC=CCCCCCCCCCC(O)=O AHANXAKGNAKFSK-UHFFFAOYSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 238000001790 Welch's t-test Methods 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 201000010038 accommodative spasm Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940109449 antisedan Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229940090983 atropine ophthalmic ointment Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- GMTYREVWZXJPLF-AFHUBHILSA-N butorphanol D-tartrate Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-AFHUBHILSA-N 0.000 description 1
- 229960001590 butorphanol tartrate Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 239000003479 dental cement Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- PRHHYVQTPBEDFE-UHFFFAOYSA-N eicosatrienoic acid Natural products CCCCCC=CCC=CCCCCC=CCCCC(O)=O PRHHYVQTPBEDFE-UHFFFAOYSA-N 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229960004882 medetomidine hydrochloride Drugs 0.000 description 1
- CVRPVRHBAOPDIG-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-(2-methylprop-2-enoyloxy)ethyl 1,3-dioxo-2-benzofuran-5-carboxylate Chemical compound COC(=O)C(C)=C.CC(=C)C(=O)OCCOC(=O)C1=CC=C2C(=O)OC(=O)C2=C1 CVRPVRHBAOPDIG-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 238000012014 optical coherence tomography Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- -1 pH regulators Substances 0.000 description 1
- YIYBQIKDCADOSF-UHFFFAOYSA-N pent-2-enoic acid Chemical compound CCC=CC(O)=O YIYBQIKDCADOSF-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000004436 pseudomyopia Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明に係る近視進行抑制剤は、眼軸長の伸長を抑制する軸性近視の進行抑制剤であって、オメガ3脂肪酸を含有する。この近視進行抑制剤は、オメガ3脂肪酸が眼軸長の伸長抑制に効果があることを初めて実証した結果に基づいてなされた発明である。従来、オメガ3脂肪酸は遠視に効果があることが報告されていたが、本発明者は、オメガ3脂肪酸が、眼軸長の伸長を抑制して軸性近視の進行を抑制できるという新しい効果を発見した。
オメガ3脂肪酸としては、α−リノレン酸(ALA、all−cis−9,12,15−オクタデカトリエン酸)、ステアリドン酸(STD、all−cis−6,9,12,15−オクタデカテトラエン酸)、エイコサトリエン酸(ETE、all−cis−11,14,17−エイコサトリエン酸)、エイコサテトラエン酸(ETA、all−cis−8,11,14,17−エイコサテトラエン酸)、エイコサペンタエン酸(EPA、all−cis−5,8,11,14,17−エイコサペンタエン酸)、ドコサペンタエン酸(DPA、all−cis−7,10,13,16,19−ドコサペンタエン酸)、ドコサヘキサエン酸(DHA、all−cis−4,7,10,13,16,19−ドコサヘキサエン酸)、テトラコサペンタエン酸(all−cis−9,12,15,18,21−テトラコサペンタエン酸)、テトラコサヘキサエン酸(ニシン酸、all−cis−6,9,12,15,18,21−テトラコサヘキサエン酸)を挙げることができる。なかでも、α−リノレン酸、エイコサペンタエン酸及びドコサヘキサエン酸から選ばれる1又は2以上の不飽和脂肪酸であることが好ましい。
近視進行抑制剤の剤形は、特に限定されないが、経口摂取剤であることが好ましい。剤形としては、錠剤、カプセル等の内服薬のような剤形とすることが好ましい。一方、局所投与であってもよいが、その場合は、ドラッグデリバリーシステム(Drug Delivery System、DDS)を使用する必要がある。
本発明に係る近視進行抑制剤は、オメガ3脂肪酸を含有する機能性食品とすることができる。機能性食品としては、健康食品、機能性表示食品、健康補助食品、栄養機能食品、特別用途食品、特定保険用食品又は通常の食品等を挙げることができる。これらの食品は、オメガ3脂肪酸を含むため、軸性近視の発症・進行が起こり易い特に成長期の小児や若年層に対して効果的である。また、これら以外であっても、眼軸伸長が原因で起こる症状・疾患に対して好ましい。
本発明に係る眼科用組成物は、医薬とすることができる。眼科用組成物を含む医薬は、眼軸長の伸長の抑制用途(軸性近視の進行抑制薬)、眼軸長を短くする軸性近視の治療用途(軸性近視の治療薬)、軸性近視が原因で発症する眼疾患の予防用途(軸性近視が原因で発症する眼疾患の予防薬)に使用される。特に軸性近視の発症・進行が起こり易い成長期の小児、若年層に対する医薬としてより好ましい。
近視モデル動物により、オメガ3脂肪酸での近視抑制実験を行った。近視モデル動物として、マウス(C57BL/6Jマウス、オス3週令)を使用した。マウスに対し、ドミトール(日本全薬工業株式会社)、ベトルファール(Meiji Seikaファルマ株式会社)及びミダゾラム(サンド株式会社)の3種混合麻酔を麻酔し、ハサミで頭蓋を露出させた。頭蓋に支柱を立設し、歯科用セメント(Super−Bond、サンメディカル株式会社)で固定した。その支柱は、調節器具をナットで固定できるようにねじ山が設けてある。
眼軸長の測定は、スペクトラルドメイン光コヒーレンストモグラフィー(Envisu R4310、Leica社製)を用いた。屈折値の測定は、マウス用赤外線フォトリフレクター(Infrared photorefractor for mice)を用いた。
測定時瞳孔を安定させるためにミドリンP(登録商標、参天製薬株式会社)を使用した。また、麻酔は、三種混合麻酔(塩酸メデトミジン(ドミトール/登録商標、日本全薬工業株式会社)、ミタゾラム(ドルミカム/登録商標、アステラス製薬株式会社)、酒石酸ブトルファノール(ベトルファール/登録商標、Meiji Seika株式会社)を用いた。麻酔覚醒時には塩酸アチパメゾール(アンチセダン/登録商標、日本全薬工業株式会社)を使用した。
図1及び図2の結果より、屈折は、オメガ6脂肪酸餌群では−30Dを装着すると有意に近視になるのに対し、オメガ3脂肪酸餌では−30Dを装着しても近視は有意に抑制されていた。また、眼軸長も、オメガ6脂肪酸餌群では−30Dで有意に長くなるのに対し、オメガ3脂肪酸餌群では−30Dを装着しても有意に抑制されていた。これらの結果より、オメガ3脂肪酸による近視抑制に効果があることが確認された。なお、有意差については、welch−t検定を実施し、*はp<0.05(有意差あり)、**はp<0.01(高度に有意差あり)であることを示している。
実験1のように、オメガ3脂肪酸リッチの餌を食べたマウスは、近視誘導眼(−30D)の近視が抑制された。そのため、実験2では、オメガ3脂肪酸を含有する餌が眼球内でどのような働きをしているかを調べるため、眼球を摘出し、脂質分子種を包括的に捉えることのできる液体クロマトグラフィータンデム型質量分析(LC−MS/MS)を行った。
Claims (7)
- 眼軸長の伸長を抑制する軸性近視の進行抑制剤であって、オメガ3脂肪酸を含有する、ことを特徴とする近視進行抑制剤。
- 前記オメガ3脂肪酸が、α−リノレン酸、エイコサペンタエン酸及びドコサヘキサエン酸から選ばれる1又は2以上の不飽和脂肪酸のである、請求項1に記載の近視進行抑制剤。
- 前記オメガ3脂肪酸が、亜麻仁油、エゴマ油及びシソ油から選ばれる1又は2以上の油から注出されるものである、請求項1又は2に記載の近視進行抑制剤。
- 剤形が経口摂取剤である、請求項1〜3のいずれか1項に記載の近視進行抑制剤。
- 請求項1〜4のいずれか1項に記載の近視進行抑制剤を含む、機能性食品。
- オメガ3脂肪酸を含有する、眼科用組成物。
- 軸性近視の進行抑制若しくは治療又は該軸性近視が原因で発症する眼疾患を予防する、請求項6に記載の眼科用組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019031932 | 2019-02-25 | ||
JP2019031932 | 2019-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2020138964A true JP2020138964A (ja) | 2020-09-03 |
Family
ID=72279902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020029934A Pending JP2020138964A (ja) | 2019-02-25 | 2020-02-25 | 近視進行抑制剤、機能性食品及び眼科用組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2020138964A (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112057444A (zh) * | 2020-09-17 | 2020-12-11 | 温州医科大学 | 巩膜脂代谢通路干预调节剂或脂代谢调节药物作为抑制近视屈光变负和眼轴延长药物的应用 |
CN114053407A (zh) * | 2020-09-17 | 2022-02-18 | 温州医科大学 | 一种通过调节眼巩膜脂代谢来抑制近视的应用 |
-
2020
- 2020-02-25 JP JP2020029934A patent/JP2020138964A/ja active Pending
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112057444A (zh) * | 2020-09-17 | 2020-12-11 | 温州医科大学 | 巩膜脂代谢通路干预调节剂或脂代谢调节药物作为抑制近视屈光变负和眼轴延长药物的应用 |
CN114053407A (zh) * | 2020-09-17 | 2022-02-18 | 温州医科大学 | 一种通过调节眼巩膜脂代谢来抑制近视的应用 |
WO2022057778A1 (zh) * | 2020-09-17 | 2022-03-24 | 温州医科大学 | 一种通过调节眼巩膜脂代谢来抑制近视的应用 |
WO2022057234A1 (zh) * | 2020-09-17 | 2022-03-24 | 温州医科大学 | 巩膜中脂代谢通路干预调节剂或脂代谢调节药物作为抑制近视屈光度变负和眼轴延长药物的应用 |
CN114053407B (zh) * | 2020-09-17 | 2023-08-29 | 极目峰睿(上海)生物科技有限公司 | 一种通过调节眼巩膜脂代谢来抑制近视的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1706106B1 (en) | Use of highly concentrated compositions of selected n-3 fatty acids for the treatment of central nervous system disturbances | |
RU2260423C2 (ru) | Этил-эпк с высокой степенью чистоты и другие производные эпк для психиатрических и неврологических расстройств | |
US6417233B1 (en) | Ubiguinone-containing composition suitable for promoting enhanced intramitochondrial transportation of ubiguinones and methods of using same | |
EP2755647B1 (en) | Use of omega fatty acids for treating disease | |
CA2801145C (en) | N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament | |
US20110244052A1 (en) | Polyunsaturated fatty acids for improving vision | |
CN114053407B (zh) | 一种通过调节眼巩膜脂代谢来抑制近视的应用 | |
JP2020138964A (ja) | 近視進行抑制剤、機能性食品及び眼科用組成物 | |
US10905671B2 (en) | Method of using omega 3 fatty acids to treat diseases which involve damage to the nervous system | |
HUE028065T2 (en) | Preparations for the treatment of neurological disorders | |
AU2021346006A9 (en) | Application of regulation of eye sclera lipid metabolism to inhibit myopia | |
WO2009018333A2 (en) | Dha and pedf, a therapeutic composition for nerve and retinal pigment epithelial cells | |
ITMI20090284A1 (it) | Uso di inibitori della serina palmitoiltrasferasi per la prevenzione e il rallentamento delle degenerazioni retiniche ereditarie e relative composizioni | |
JP2024517782A (ja) | 近視を治療するための方法及び薬物組成物 | |
US6833142B2 (en) | Formulation for the prevention and treatment of multiple sclerosis and other demyelinating conditions | |
WO2015165507A1 (en) | Treatment of eye diseases using omega 3 fatty acids and aa/epa blood ratio | |
CA2545190A1 (en) | Agent for preventing and treating language disorders | |
WO2013191167A1 (ja) | ヘアレス動物の眼瞼状態の変化方法 | |
US20140343143A1 (en) | Use of highly concentrated compositions of selected n-3 fatty acids for the treatment of central nervous system disturbances | |
WO2013191168A1 (ja) | 完全フロイントアジュバント投与による眼瞼状態の変化方法 | |
JP2016023163A (ja) | γ−リノレン酸を含む神経細胞の酸化ストレス軽減剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230224 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240109 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240311 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240509 |